Docetaxel and Doxorubicin Codelivery by Nanocarriers for Synergistic Treatment of Prostate Cancer

Combination chemotherapy has been proven to be an efficient strategy for the treatment of prostate cancer (PCA). However, the pharmacokinetic distinction between the relevant drugs is an insurmountable barrier to the realization of their synergistic use against cancer. To overcome the disadvantages...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ke, Zhan, Wenhua, Chen, Yulong, Jha, Rajiv Kumar, Chen, Xueli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930690/
https://www.ncbi.nlm.nih.gov/pubmed/31920642
http://dx.doi.org/10.3389/fphar.2019.01436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930690/
https://www.ncbi.nlm.nih.gov/pubmed/31920642
http://dx.doi.org/10.3389/fphar.2019.01436

Ejemplares similares